It is well known that the incidence of EGFR mutations is higher in Asian patients with lung adenocarcinoma (LUAD), and the overall EGFR mutation prevalence in the mainland Chinese population is 50.2% (22). Here, EGFR is linked to lung adenocarcinoma.